Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review ; volume:23 ; number:1 ; day:28 ; month:9 ; year:2024 ; pages:1-20 ; date:12.2024
Cardiovascular diabetology ; 23, Heft 1 (28.9.2024), 1-20, 12.2024
- Urheber
-
Zheng, Haixiang
Sechi, Leonardo Antonio
Navarese, Eliano Pio
Casu, Gavino
Vidili, Gianpaolo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-024-02434-5
- URN
-
urn:nbn:de:101:1-2412142113189.676191561102
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zheng, Haixiang
- Sechi, Leonardo Antonio
- Navarese, Eliano Pio
- Casu, Gavino
- Vidili, Gianpaolo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease
Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression
The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque
Single‐cell transcriptomics stratifies organoid models of metabolic dysfunction‐associated steatotic liver disease
Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease
IFNγ-IL12 axis regulates intercellular crosstalk in metabolic dysfunction-associated steatotic liver disease
Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease and gallbladder polyp development: an observational study
A metabolic dysfunction-associated steatotic liver acinus biomimetic induces pancreatic islet dysfunction in a coupled microphysiology system
Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study
Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease
Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression
The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque
Single‐cell transcriptomics stratifies organoid models of metabolic dysfunction‐associated steatotic liver disease
Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease
IFNγ-IL12 axis regulates intercellular crosstalk in metabolic dysfunction-associated steatotic liver disease
Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease and gallbladder polyp development: an observational study
A metabolic dysfunction-associated steatotic liver acinus biomimetic induces pancreatic islet dysfunction in a coupled microphysiology system
Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study
Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease
Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression
The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque
Single‐cell transcriptomics stratifies organoid models of metabolic dysfunction‐associated steatotic liver disease
Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease
IFNγ-IL12 axis regulates intercellular crosstalk in metabolic dysfunction-associated steatotic liver disease
Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease and gallbladder polyp development: an observational study
A metabolic dysfunction-associated steatotic liver acinus biomimetic induces pancreatic islet dysfunction in a coupled microphysiology system
Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study